BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS

Path forward for ALS is a registrational Phase 3b U.S. clinical trial Biologics License Application to be withdrawn without prejudice Conference call and webcast at 8:30am ET today NEW YORK, Oct. 18, 2023 -- (Healthcare Sales & Marketing Network) ... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn, stem cell
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news